C07K 2317/567
Framework region [fr]
Official title: Framework region [FR]
C07K2317/567 (Framework region [fr]) appears on 1,759 US grants and 3,173 published applications in this corpus.
Search patents in C07K- Granted patents
- 1,759
- Published applications
- 3,173
- Assignees
- 967
- Inventors
- 5,283
- Latest grant
- 15 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1996 | 1 | 0 |
| 1997 | 0 | 0 |
| 1998 | 6 | 0 |
| 1999 | 5 | 0 |
| 2000 | 1 | 0 |
| 2001 | 1 | 0 |
| 2002 | 1 | 8 |
| 2003 | 1 | 15 |
| 2004 | 7 | 19 |
| 2005 | 5 | 48 |
| 2006 | 6 | 41 |
| 2007 | 8 | 50 |
| 2008 | 16 | 56 |
| 2009 | 22 | 77 |
| 2010 | 29 | 77 |
| 2011 | 46 | 116 |
| 2012 | 57 | 99 |
| 2013 | 76 | 126 |
| 2014 | 90 | 146 |
| 2015 | 87 | 144 |
| 2016 | 104 | 173 |
| 2017 | 110 | 207 |
| 2018 | 133 | 210 |
| 2019 | 137 | 212 |
| 2020 | 145 | 191 |
| 2021 | 126 | 226 |
| 2022 | 129 | 200 |
| 2023 | 90 | 188 |
| 2024 | 122 | 180 |
| 2025 | 122 | 216 |
| 2026 | 76 | 148 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Anti-VLA-4 antibodies15 Sep 2026US 12,734,236 B2Biogen MA Inc.
- Antibody that binds to VEGF and IL-1BETA and methods of use15 Sep 2026US 12,735,477 B2Hoffmann-La Roche Inc.
- Anti-TIGIT antibodies and methods of use15 Sep 2026US 12,735,483 B2Industrial Technology Research Institute
- Multi-domain CD1a antagonist/PD-1 agonist antibody molecules15 Sep 2026US 12,735,491 B2Immunocore Limited
- Immunoglobulin variable domains1 Sep 2026US 12,723,072 B2Ablynx N. V.
- Lipid nanoparticles and methods of manufacture and use thereof8 Oct 2026US 2026/0306659 A1Ablynx N. V.
- Multi-domain molecules8 Oct 2026US 2026/0308260 A1Immunocore Limited
- Il12rb2 binding molecules and methods of use8 Oct 2026US 2026/0308265 A1Synthekine, Inc.
- Antibody that binds to c3bbb8 Oct 2026US 2026/0308278 A1Hoffmann-La Roche Inc.
- Sequence-based high throughput method generating camelids antibodies to cover broad epitopes with high-resolution8 Oct 2026US 2026/0308807 A1Zhejiang Nanomab Technology Center Co. Ltd.
Most cited
By later US patents
- Human monoclonal antibodies to programmed death ligand 1 (PD-L1)628US 7,943,743 B2Medarex, Inc. · 2011
- Anti-PD-L1 antibodies, compositions and articles of manufacture459US 8,217,149 B2Genentech, Inc. · 2012
- Immunoglobulins devoid of light chains285US 6,005,079 AVrije Universiteit Brussels · 1999
- Anti-PD1 antibodies and their use as therapeutics and diagnostics285US 8,735,553 B1BeiGene, Ltd. · 2014
- CDR grafted anti-CEA antibodies and their production238US 5,877,293 ACelltech Therapeutics Limited · 1999